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Free radicalsThe homodimeric flavohemeprotein endothelial nitric oxide synthase (eNOS) oxidizes L-arginine to
L-citrulline and nitric oxide (NO), which acutely vasodilates blood vessels and inhibits platelet aggregation.
Chronically, eNOS has a major role in the regulation of blood pressure and prevention of atherosclerosis by
decreasing leukocyte adhesion and smoothmuscle proliferation. However, a disturbed vascular redox balance
results in eNOS damage and uncoupling of oxygen activation from L-arginine conversion. Uncoupled eNOS
monomerizes and generates reactive oxygen species (ROS) rather than NO. Indeed, eNOS uncoupling has been
suggested as one of the main pathomechanisms in a broad range of cardiovascular and pulmonary disorders
such as atherosclerosis, ventricular remodeling, and pulmonary hypertension. Therefore, modulating
uncoupled eNOS, in particular eNOS-dependent ROS generation, is an attractive therapeutic approach to
preventing and/or treating cardiopulmonary disorders, including protective effects during cardiothoracic
surgery. This review provides a comprehensive overview of the pathogenetic role of uncoupled eNOS in both
cardiovascular and pulmonary disorders. In addition, the related therapeutic possibilities such as
supplementation with the eNOS substrate L-arginine, volatile NO, and direct NO donors as well as eNOS
modulators such as the eNOS cofactor tetrahydrobiopterin and folic acid are discussed in detail.lsevier Inc.© 2010 Published by Elsevier Inc.ContentsIntroduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 766
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It has been 30 years since Furchgott and Zawadski demonstrated
that the endothelium produces a mysterious “endothelium-derived
relaxing factor,” which is responsible for vascular smooth muscle
relaxation [1]. This was followed by the remarkable observation that
this factor was the freely diffusible gas nitric oxide (NO) [2]. Today, NO
is regarded as one of the body's most versatile molecules. It is a
neurotransmitter, second messenger, inflammatory marker, and
therapeutic agent that is generated by nitric oxide synthases (NOS).
NOS catalyze the conversion of the amino acid L-arginine[3] and
molecular oxygen to L-citrulline and NO, aided by cofactors. Three
NOS isoforms have been identified, i.e., neuronal NOS (NOS-I),
inducible NOS (NOS-II), and endothelial NOS (NOS-III; eNOS).
Endothelial NOS, as its name suggests, is mainly found in the
endothelial lining of the blood vessels but also in the cardiomyocytes
[4], airway epithelium [5], tubular cells of the kidney [6], and other
organ systems. The cardiovascular system relies on eNOS for optimal
function, most notably with NO as the principle mediator of flow-
mediated dilation. In addition to blood pressure regulation, eNOS-
derived NO is also responsible for inhibition of platelet aggregation,
leukocyte adhesion, and smooth muscle cell proliferation (see Fig. 1
for the structure of eNOS) [7]. Consequently, functional impairment
of this enzyme may result in endothelial dysfunction, leading to both
pulmonary and systemic hypertension. Most actions of NO are
mediated via the production of cGMP by guanylate cyclase, resultingFig. 1. Molecular structures of eNOS monomer and dimer. (A) Secondary structure of the e
separated by a calmodulin (CaM) binding site. (B) Detail of the eNOS dimer. The Zn ion is
dimerization. The electron transfer is visualized below, NADPH-oxidase donating an electron
and nitric oxide. Tetrahydrobiopterin (BH4) further stabilizes the dimer. Zn, zinc; Arg, arginin a decreased intracellular calcium (Ca2+) concentration. Lower
intracellular Ca2+ results in relaxation of the vascular smooth
muscle layer and ultimately in vasodilatation and a decrease in
blood pressure.
In this review, we discuss the molecular basis of eNOS uncoupling,
the regulation of eNOS activity, its physiological functions in the
cardiopulmonary system, and its role in the physiopathology of
various cardiovascular and pulmonary diseases.
Molecular structure and function
eNOS is a homodimer that binds a number of different cofactors,
which are required to convert L-arginine and O2 to L-citrulline and NO.
Each eNOS monomer has a bidomain structure. The N-terminus
comprises the oxygenase domain and contains tetrahydrobiopterin
(BH4), heme iron, and L-arginine binding sites. L-Arginine and BH4
promote enzyme dimerization and both act as a stabilizer of the active
dimeric form [8,9]. The heme group is also essential for dimerization
[10]. Further stabilization is generated by a zinc thiolate (ZnS4) cluster
formed by a zinc ion between two cysteine residues from each
monomer. This cluster is responsible for the integrity of the BH4
binding site [11]. The C-terminus is the reductase domain with
binding sites for two flavins, flavin adenine dinucleotide (FAD) and
flavin mononucleotide (FMN), and NADPH [12]. Electrons are
produced by oxidation of NADPH to NADP+ at the flavin domain of
each monomer [12]. These electrons are then transferred, one at aNOS monomer. The oxygenase (N-terminal) and reductase (C-terminal) domains are
responsible for connecting the monomers at the heme groups, which are resistant to
to be ultimately used to convert arginine and oxygen to the reaction products citrulline
ine binding site; FMN, flavin mononucleotide; FAD, flavine adenine dinucleotide.
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reduction of molecular oxygen (O2) to O2− takes place. Bound
L-arginine is then converted to NO and the by-product L-citrulline.
This electron transferontoheme ismediatedby FAD [13]. The oxygenase
is linked to the reductase domain by an inhibitory calmodulin binding
domain. To be active, eNOS has to be deinhibited by the binding of two
calcium-activated calmodulins, which secure the electron transfer
from the reductase to the oxygenase domain (Fig. 2) [14].
Regulation of eNOS
eNOS is predominantly targeted to the sarcolemmal caveolae,
which are invaginations of the plasma membrane. Here the enzyme is
bound by posttranslational myristoylation and palmitoylation to
caveolin-1, a resident coat protein that inhibits eNOS activity.
Caveolin-1 interacts with the calmodulin (CaM) binding sites and
inhibits the electron transfer from NADPH at the reductase to the
heme molecule in the oxygenase domain. At a cellular level, eNOS is
therefore activated by a calcium-mediated disruption of the eNOS–
caveolin heteromeric complex. Caveolin-free eNOS is then translo-
cated from the caveolae to the cytoplasm. Its enzymatic function there
is greatly upregulated, including also Ca2+-independent steps. As a
result, the electron flow from the reductase to the oxygenase domain
is initiated, and NO is produced. In addition, in the caveolae the
substrate L-arginine is recycled from L-citrulline, ensuring a sufficient
pool for eNOS [15–17]. In addition, eNOS activity is influenced by
posttranslational modifications, such as calcium influx, and phos-
phorylation at various amino acid residues [18]. Calcium-activated
CaM is essential for rapid enzyme activation, although in vivo eNOS
may become calcium independent through a reduction in CaM
dissociation from activated eNOS [19]. Phosphorylation is of key
importance in regulating the overall function, activation, and,
potentially, coupling of eNOS. This includes phosphorylation of
calmodulin, caveolin, and amino acid residues on eNOS itself. The
production of both NO and superoxide by eNOS can be modulated by
protein kinase Cα (PKCα)-mediated phosphorylation of calmodulin
and caveolin. Phosphorylation of eNOS at Ser1177 is pivotal in theFig. 2. Schematic overview of eNOS uncoupling. In the presence of enough BH4, the eNOS di
arrow). BH4 binds the oxygenase domain of eNOS and stabilizes the dimer. However, in
concentration drops, the eNOS dimer will uncouple into two monomers, which are less ef
reaction self-perpetuates because ROS generated by uncoupled eNOS oxidize BH4 themselve
BH2, dihydrobiopterin; HSP, heat shock protein.direct regulation of superoxide versus NO generation, altering both
the calcium sensitivity of the enzyme and the rate of reaction product
formation [20]. In detail, direct phosphorylation of Ser1177 by
adenine monophosphate kinase (AMPK) enhances eNOS activity by
promoting its association with heat shock protein 90 [21]. This is also
true for the uncoupled eNOS, for which Akt-mediated phosphoryla-
tion of Ser1177markedly enhancesmaximal superoxide generation at
low levels of calcium, making NO generation largely calcium
independent [19]. However, phosphorylation at Thr495 at the CaM
binding domain prevents the increase in catalytic activity of eNOS by
hindering the association of CaM with eNOS [22]. In addition,
phosphorylation at Ser633 in the FMN binding domain has been
associated with increased enzyme activity after initial activation by
Ca2+ influx and Ser1177 phosphorylation [18]. eNOS can also be
phosphorylated at Ser114 and Ser615, but the functions of these
phosphorylation sites remain controversial [23].
BH4 is obligatory for optimal eNOS activity. First, it ensures normal
function at the heme catalytic site. In the absence of BH4, reduction of
the ferric ion of the eNOS heme group translates to the formation of an
Fe(II) dioxygen complex, resulting in superoxide formation. In the
presence of BH4, iron–oxy species are formed, which participate in L-
arginine hydroxylation and thus in NO generation. Second, it increases
eNOS affinity for L-arginine [24]. Third, it is hypothesized to play a role
in the electron transfer, being converted to a BH3 radical during the
first catalytic reaction [25]. Fourth, BH4 interacts with amino acid
residues from both monomers to stabilize dimerization [26]. In
addition, BH4 can act as a modest scavenger of reactive oxygen (ROS)
and nitrogen species.
BH4 can be oxidized by ROS, leading to a reduction in vascular
BH4 and an increase in vascular BH2 availability [27]. A lack of this
crucial cofactor results in decreased eNOS function and a further
increase in ROS production combined with a decrease in NO
production [28,29]. In addition the oxidation product, BH2, is a
competitive BH4 antagonist [30].
BH4 was initially described as the oxygen acceptor and cofactor for
aromatic amino acid hydroxylases, involved in neurotransmitter
biosynthesis. In eNOS, however, heme is the oxygen receptor andmer produces abundant amounts of NO (thick arrow) and a small fraction of ROS (thin
absence of BH4, when there is more BH4 oxidized to BH2, and/or when the HSP-90
ficient in the production of NO and generate large amounts of ROS (thick arrow). The
s. Arg, Arginine; Cit, citrulline; ROS, reactive oxygen species; BH4, tetrahydrobiopterin;
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pathways, i.e., a de novo and a salvage pathway (Fig. 3). The de novo
synthesis of BH4 starts with guanidine triphosphate, which is
converted by guanidine triphosphate cyclohydrolase-1 (GTPCH-1)
and sepiapterin reductase to BH4. GTPCH-1 is the rate-limiting
enzyme in the biosynthesis of BH4. It is inhibited by the specific
GTPCH feedback regulatory protein and is under positive feedback by
phenylalanine [31]. This regulation takes place by altering the
transcription levels, and thus, the production of BH4 is largely
dependent on GTPCH-1 expression. Transcription is increased by
inflammatory factors such as tumor necrosis factor-α, interleukin-1,
interferon-γ, and lipopolysaccharides [32]. GTPCH-1 is localized in the
caveolar microdomains of the cardiomyocyte together with caveolin-
1 and eNOS [33], where it provides a continual source of BH4. GTPCH-1
expression is also determined by the GTPCH-1 haplotype [34]. Certain
autosomal-dominant inherited mutations in the GTPCH-1 enzyme
lead to congenital BH4 deficiency and neurological symptoms known
as dopa-responsive dystonia [35]. In mammals, the main salvage
pathway progresses through dihydrofolate reductase (DHFR) and
dihydropteridin reductase (DHPR). DHFRmainly activates folic acid to
5-methyltetrahydrofolate and also regenerates BH4 from its oxidized
form BH2. DHPR uses the quinonoid form of BH2 as substrate.
Uncoupling of eNOS
Uncoupling of eNOS can be visualized by SDS–polyacrylamide gel
electrophoresis as a loss of the eNOS dimer and an increase in the
monomer-to-dimer ratio [36]. The uncoupled state can thus also be
interpreted as an altered quaternary structure of the enzyme.
Vasquez-Vivar et al. [30] demonstrated the effects of BH4 on the
balance between NO and superoxide formation. In absence of BH4,
eNOS becomes uncoupled and cannot reach its normal NO-
generating abilities. Once eNOS is uncoupled because of decreased
bioavailability of BH4, the uncoupling propagates because uncoupled
eNOS generates superoxide, which will oxidize the remaining BH4Fig. 3. Cellular pathways involving tetrahydrobiopterin (BH4). Guanidine triphosphate cyclo
regulatory protein), which is influenced by statins and inflammatory mediators such as TN
6-pyruvoyltetrahydropterin synthase (PTPS). Sepiapterin is converted into dihydrobiopterin
(DHFR), which also reduces dihydrofolate (DHF) to tetrahydrofolate (THF). BH4 assists in e
(AMPK). AMPK is inhibited by the antidiabetic agent metformin, and AMPK itself inhibits t[27]. Superoxide may react with NO, forming peroxynitrite [37]. The
increased activity of enzymes such as NADPH oxidases ignites a
cascade of radical formation by producing superoxide as a kindling
radical. Bursts of peroxynitrite oxidize BH4 to BH3, further increasing
eNOS uncoupling, starting a bonfire of radical production by eNOS.
Peroxynitrite can also lead to irreversible nitration of tyrosine
residues on other proteins [38], causing impaired phosphorylation
and enzymatic dysfunction [39].
Importantly, elevated eNOS expression, without a parallel increase
in BH4, results in eNOS uncoupling because of an imbalance between
the cofactor and the enzyme [40]. Crabtree et al. [41] investigated the
stoichiometry of intracellular BH4/eNOS interactions and demonstrat-
ed a striking linear relationship between eNOS activity and cellular
BH4 levels, with eNOS uncoupling occurring when the eNOS:BH4
molar ratio exceeded 1. Increasing intracellular BH2 concentration in
the presence of a constant eNOS:BH4 ratio was sufficient to induce
eNOS-dependent superoxide production, indicating that eNOS/BH4
reaction stoichiometry has a tandem role with the intracellular BH4:
BH2 ratio (rather than absolute plasma concentrations of BH4) in
determining eNOS uncoupling, even when exogenous oxidative stress
is absent. In another recent study, Heiss et al. [42] demonstrated that a
decrease in BH4 levels activates NF-E2-related factor, which leads to a
reduction in eNOS protein levels in human endothelial cells. Thus, the
stoichiometric balance between BH4 and eNOS is maintained, eNOS is
kept in a coupled state, and ROS production is reduced. Crabtree et al.
[41] showed that murine endothelial cells contain large amounts of
DHFR and that reduction of DHFR activity by methotrexate, or genetic
knockdown of DHFR by RNA interference, resulted in oxidation of BH4
to BH2 with subsequent eNOS uncoupling. DHFR can regenerate BH4
from BH2 and preserve eNOS coupling by helping to maintain a better
BH4:BH2 ratio, especially when both are scarce.
The essential role of L-arginine in keeping eNOS coupled is
debatable. It is unlikely that plasma L-arginine levels would fall
below the critical concentration for eNOS activity in vivo, as the
plasma level of L-arginine is 30 times higher than the eNOS KMhydroxylase (GTPCH) is inhibited by glucocorticoids, cGMP, and GFRP (GTPCH feedback
Fα. Nitric oxide stimulates GTPCH, which activates sepiapterin reductase (SR) through
(BH2) andmay be further reduced to tetrahydrofolate (BH4) by dihydrofolate reductase
NOS coupling, which is activated by phosphorylation by AMP-activated protein kinase
he 26S proteasome, thereby inhibiting breakdown of GTPCH.
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recycled by the cell [43]. An increased intracellular breakdown by
arginases, however, can lead to a very local, subcellular decrease in
intracellular L-arginine. As such, arginases, expressed in endothelial
cells, can compete with eNOS for their common substrate [44] and can
therefore also have downregulating effects on eNOS [45]. The eNOS
inhibitor asymmetric dimethylarginine (ADMA) directly inhibits
eNOS, and it also inhibits cellular L-arginine uptake by endothelial
cells. Therefore, a decreased L-arginine:ADMA ratio can result in
reduced NO formation by eNOS. Indeed, Antoniades et al. [46]
demonstrated a strong inverse association between serum ADMA
and levels of eNOS dimer, in both human arteries and human veins.
Furthermore, increased ADMA plasma concentrations are associated
with oxidative stress within the vessels and the development of
endothelial dysfunction [47]. Thus rather than changes in L-arginine,
changes in ADMA seem to trigger eNOS uncoupling. However, Druhan
et al. [48] demonstrated that, although ADMA can uncouple eNOS and
elevate ROS generation in the absence of BH4, this is not the fact when
adequate levels of L-arginine are present. Also, in this study ADMA and
L-arginine elevated ROS produced by uncoupled eNOS in equal
fashions. This may indicate that ADMA is not responsible for eNOS
uncoupling under physiological conditions.
The ZnS4 cluster in the eNOS oxygenase domain, formed by a zinc
ion and two cysteine residues from each monomer, is positioned
equidistant from each heme group and is responsible for the
maintenance of the integrity of the BH4 binding site [11]. Mutation
in this cluster prevents the binding of zinc, BH4, or L-arginine and
eliminates enzyme activity [49], suggesting that stabilization of the
dimer interface by the zinc thiolate center is one of the keys for
catalytic activity. Exposing the isolated eNOS enzyme to peroxynitrite,
a by-product of the interaction between excessive NO and O2•−, leads
to the oxidation of the zinc thiolate cluster, which uncouples eNOS.
Recently, Chen et al. [50] demonstrated that the dimer stabilization
induced by BH4 does not require zinc occupancy in this thiolate
cluster. Although peroxynitrite treatment induced loss of Zn binding
and compromised eNOS activity, incubation with a zinc chelator did
not alter eNOS activity.
Role of eNOS uncoupling in the cardiovascular system
Hypertension and heart failure
In mice, gene expression of eNOS influences vascular tone and
hence is a major determinant of blood pressure regulation [51]. eNOS
uncoupling in hypertension was first shown by Mollnau et al. [52] in
an in vivo rat angiotensin II infusion model. Where deletion of the
eNOS gene causes systemic hypertension [51], overexpression results
in a reduction of blood pressure [53]. Landmesser et al. [27]
demonstrated the pathogenetic role of eNOS uncoupling in DOCA
salt hypertension. Later, Takimoto et al. [54] confirmed the key role of
eNOS uncoupling in pressure-overload-induced ventricular remodel-
ing using a model of transverse aortic constriction. They demonstrat-
ed that oral administration of BH4 to wild-type mice prevented
cardiac hypertrophy and dilation, improved heart function, and
inhibited eNOS uncoupling with a subsequent increase in NO
synthesis and a decrease in ROS generation. In addition, this group
showed that pressure overload in eNOS−/− mice resulted in less
cardiac hypertrophy, dilation, and a decrease in myocardial fibrosis
because no eNOS was available to become uncoupled, and conse-
quently, there was no detrimental NOS-dependent superoxide
generation. Further, Moens et al. [55] demonstrated that oral
administration of BH4 can restore uncoupled eNOS and reverse
preexisting ventricular hypertrophy, fibrosis, and myocardial dys-
function. Treatment with a general antioxidant such as Tempol had no
effect on eNOS and could not produce the same positive results on
preexisting ventricular remodeling as BH4.Diabetes mellitus
Insulin resistance induces eNOS uncoupling through increased
superoxide production [56] in streptozotocin-induced diabetic LDL
receptor-deficient mice. In the vessels of rats with streptozotocin-
induced diabetes both upregulation and uncoupling of eNOS are
observed in a PKC-dependent process [57]. This is observed despite
an increase in eNOS expression, suggesting that eNOS becomes
uncoupled rather than downregulated. Diabetes mellitus (DM) type
2 is associated with increased nitrotyrosine formation mediated by
peroxynitrite and subsequent endothelial dysfunction [58]. In mice
treated with streptozotocin, which selectively destroys the β cells of
the pancreas, inducing DM, eNOS becomes uncoupled but also
expressionally upregulated [59]. This results in a decrease in BH4
levels and compensatory GTPCH-1 overexpression in the endothe-
lium of the diabetic aorta [59,60]. However, the influence of this
GTPCH-1 overexpression is limited in light of uncoupled eNOS, and a
subsequent decrease in BH4 is observed [60]. There is also evidence
that GTPCH-1 is downregulated in diabetes and not compensatorily
upregulated [61]. The dysfunction of endothelial progenitor cells in
patients with DM 2 and the consequent lack of vascular repair have
also been linked to eNOS uncoupling induced by BH4 deficiency [62].
Recently Wang et al. [63] described that a decrease in AMPK results
in abnormal activity of the 26S proteasome, leading to an accelerated
destruction of GTPCH in a streptozotocin model of DM 2 in mice. In
patients with DM 2, metformin, which activates AMPK, was shown to
reduce mortality and improve vascular function. Inhibiting the
breakdown of GTPCH-1 by the 26S proteasome via AMPK upregula-
tion is therefore an additional pathway for maintaining normal
eNOS activity.
Atherosclerosis
Oelze et al. [64] first demonstrated that eNOS uncoupling is at least
partially involved in the increased ROS formation in the vessels of
hyperlipidemic rabbits. Antoniades et al. [65] investigated the role of
BH4 in atherosclerosis using saphenous veins and internal mammary
arteries from patients with coronary artery disease (CAD) undergoing
coronary bypass surgery. They found that plasma biopterin levels are
inversely correlated with vascular biopterins, which are mostly
present in the endothelium. Vascular BH4 levels were inversely
correlated with vascular ROS generation and positively correlated
with eNOS coupling and NO-mediated endothelial function. Plasma
BH4 levels were also positively correlated with impaired endothelial
function [65] and with C-reactive protein (CRP) levels, a prototypic
marker of inflammation. The direct effects of CRP on cardiovascular
risk are debated and CRP may better be regarded a marker of
cardiovascular disease, rather than a mediator. The pathogenetic role
of eNOS uncoupling is described in Fig. 4.
Proinflammatory stimuli are sufficient to increase the amount of
circulating plasma biopterins, but fail to increase biopterin levels in
the endothelium itself, leading to endothelial dysfunction by eNOS
uncoupling. As described above, the specific GTPCH-1 haplotype of the
patient determines the levels of BH4 in plasma and vascular
endothelium [34]. This GTPCH haplotype [66] is defined by three
single-nucleotide polymorphisms, rs8007267G→A in the putative
promoter region, rs3783641A→T in intron 1, and rs10483639C→G
in the 3′ untranslated region of the GTPCH-1 gene, and is associated
with increased vascular superoxide generation by uncoupled eNOS
and decreased endothelial function, independent of other risk factors
for atherosclerosis. The existence of different GTPCH haplotypes and
genetic differences in BH4 availability may therefore be an explana-
tion for the heterogeneity in patients with coronary artery disease.
eNOS activity has not only been associated with risk factors for CAD, it
may also be of importance in its prevention. Regular aerobic exercise
reduces the risk of cardiac events, possibly through shear-stress-
Fig. 4. Involvement of eNOS in atherogenesis. Various risk factors for atherosclerosis may lead to eNOS uncoupling, causing an increase in ROS. Oxidation of BH4 to BH2 is critical in
this process. The enormous amounts of ROS cause endothelial damage, inflammation, and atherosclerosis. Depending on the GTPCH-1 haplotype, patients may be more susceptible
to this mechanism and thus coronary artery disease. Upregulation of GTPCH-1 or external supplements of BH4 may slow this process down or even reverse it.
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exercise ameliorates peripheral NO-dependent vasodilatation in
patients with chronic heart failure [67] and coronary vasomotor
activity in CAD patients [68]. Shear stress activates the tyrosine kinase
c-Src and initiates an intracellular cascade, which increases eNOS
mRNA transcription and stability in vitro [69] through activation of a
shear-stress response element on the eNOS promoter. Mice that are
heterozygous for c-Src deletion no longer display a positive
correlation between training and vascular eNOS expression, indicat-
ing that the c-Src pathway is pivotal in how physical training
modulates eNOS function [70].
Ischemic heart disease
Oxidative stress at the cellular level plays a key role in myocardial
remodeling after myocardial infarction (MI) [71,72]. Previous studies
have indicated that cardiac remodeling after MI was attenuated in
transgenic mice overexpressing eNOS, but deteriorated in eNOS−/−
mice [73]. Similarly, NO can increase angiogenesis [74] and decrease
cardiac fibrosis [75] after MI. The presence of eNOS attenuates left-
ventricular dysfunction and remodeling in a murine model of MI by
afterload-independent mechanisms, partially by decreasing myocyte
hypertrophy in the myocardium [76]. In addition, Masano et al. [77]
demonstrated in a rat model of MI that the ventricular remodeling
process after MI was associated with increased superoxide produc-
tion from the noninfarcted myocardium. Yaoita et al. [78] reported,
using a rat model, that an increase in eNOS activity by supplemen-
tation of BH4 lowers the myocardial activation of neutrophils after
surgically created coronary ligation and subsequent ischemia,
protecting both endothelial cells and cardiomyocytes from myocar-
dial inflammation. This was attributed to an eNOS-dependent
improvement in coronary arteriole endothelial function and there-
fore in myocardial perfusion. Consequently, modulating eNOS by
administration of BH4 can be considered a potential therapeutic
agent to counteract the damaging effect of ischemia through
improved coronary perfusion and to attenuate ventricular remodel-
ing and therefore preserve cardiac function. Furthermore, the
occurrence and subsequent alleviation of eNOS uncoupling after MI
were indicated by a reduction in the eNOS dimer/monomer ratio andits restoration by exogenous BH4 [55]. Supplementation with the BH4
precursor sepiapterin or the synthetic BH4 analogue 6-methyltetra-
hydropterin both improves response to endothelium-dependent
vasodilators in coronary arteries as was demonstrated in vivo in a
pig model of coronary occlusion and subsequent reperfusion [79].
However, in another paper by Vasquez-Vivar et al. [30], it was
demonstrated that sepiapterin may also uncouple eNOS by antago-
nizing BH4. Therefore, it may not always work.
Smoking
Cigarette smoke contains high amounts of radicals such as NO, O2−,
and ONOO−. Reduced availability of BH4 because of oxidation by these
radicals may cause eNOS uncoupling and this process, at least in part,
contributes to the endothelial damage and dysfunction in chronic
smokers. Supplementation of BH4 can improve vasodilatator response
in the brachial artery of chronic smokers. However, the mere
antioxidant properties of BH4 may also be responsible for this effect.
Heitzer et al. [80] found that BH4, but not tetrahydroneopterin (also a
reduced pteridine), could modify Acetylcholine-induced changes in
forearm blood flow of chronic smokers, which points to a specific effect
of BH4 on eNOS rather than its action as a nonspecific antioxidant.
Nitrate tolerance
Nitrate tolerance is defined as a decline in the vasodilatory effects
of nitroglycerin (NTG) after a period of its continuous administration.
Oxidative stress in NTG-exposed blood vessels reduces NO bioavail-
ability, resulting not only in compromised relaxation, but also in
reduced sensitivity of the vessels to endothelium-dependent vasodi-
latators. The source of NTG-induced superoxide is still unknown, but
uncoupled eNOS is considered to be a potential candidate in addition
to components of the mitochondrial respiratory chain and NADPH
oxidases. Münzel et al. [81] demonstrated in a model of NTG-treated
rats that increased endothelial O2− production is responsible for
nitrate tolerance after long-term nitrate treatment. Following these
observations they showed that eNOS protein and RNA expression is
significantly increased after NTG treatment. In nitrate-tolerant vessels
the increased production of ROS was caused by uncoupling of higher
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PKC. Ikejima et al. [82] demonstrated significantly reduced BH4 levels
possibly leading to eNOS uncoupling in aortic segments obtained from
rabbits that had been continuously treated for 7 days with transder-
mal NTG patches. However, this could not be demonstrated by
Schmidt et al. [83] using an established guinea pig model of nitrate
tolerance. Furthermore, Gori et al. [84] demonstrated that adminis-
tration of folic acid can prevent NTG-induced endothelial nitric oxide
dysfunction and nitrate tolerance in healthy male volunteers.
Cardiovascular aging
It is well documented that skeletal muscle vascular conductance
and endothelium-dependent vasodilatation are reduced with aging.
Aging in rats causes a decline in eNOS activity, which may contribute
to the development of hypertension [85]. eNOS uncoupling and a
decrease in NO bioavailability may contribute to this aging-related
decline in flow-induced vasodilatation and subsequent increase in
blood pressure. In humans, a single dose of oral BH4 could restore
endothelium-dependent dilatation in the conduit brachial artery of
sedentary older men [86]. In addition, Sindler et al. [87] found that
age-related reduction in BH4 occurred in conjunction with a decline in
flow-induced NO signaling and an increase in superoxide production
by eNOS uncoupling. Exercise training prevented this age-related loss
of BH4 and improved NO bioavailability by balancing accelerated NO
and ROS production.
eNOS uncoupling in pulmonary diseases
Pulmonary artery hypertension
Chronic hypoxia is one of the main causes of sustained pulmonary
artery hypertension (PAH) in patients with chronic obstructive lung
disease or congestive heart failure or during cardiopulmonary bypass
surgery [5,88]. Impairment of NO production is regarded as a possible
mechanism in the pathogenesis of PAH [89], as eNOS−/− mice are
more susceptible to hypoxia than wild-type controls [90]. In rats with
hypoxia-induced PAH, eNOS activity, but not eNOS expression, was
lowered, indicating that eNOS is inactivated at a posttranslational
level. Murata et al. speculated that eNOS inactivation may be caused
by a lack of dissociation between eNOS and caveolin-1, inhibiting the
translocation of eNOS to the cytosol and impairing Akt-mediated
eNOS phosphorylation at Ser1177 [91]. This is in contrast to systemic
hypertension, which showed eNOS uncoupling as the critical cause of
inactivation of the decrease in the amount of NO produced [27]. In
addition, Xu et al. [45] described a decrease in the eNOS substrate
L-arginine [45] from increased arginase II activity during PAH.
Furthermore, an increase in the endogenous eNOS inhibitor ADMA
during PAH has been described [92]. Elevation of ADMA is indeed a
potential pathogenetic mechanism for pulmonary hypertension in
patients with congenital heart disease [93]. ADMA is mostly elevated
in the pulmonary vascular endothelium of PAH patients in areas of
intimal fibrotic and plexiform lesions, compared to healthy patients.
Acute lung injury and acute respiratory distress syndrome
Acute lung injury (ALI) and acute respiratory distress syndrome
(ARDS) are acute inflammatory states, which are characterized by a
sudden onset of dyspnea, severe hypoxemia, neutrophil pulmonary
sequestration, and pulmonary edema secondary to disruption of
pulmonary capillary integrity. They remain significant causes of
morbidity and mortality in hospitalized patients [94]. Sharma et al.
[95] used a lipopolysaccharide (LPS)-induced mouse model of ALI to
demonstrate that LPS increases the level of ADMA in endothelial cells.
ADMA may be responsible for NOS uncoupling transiently at early
stages of ALI. Peak superoxide production occurred 2 h after exposureto LPS. It was not possible to determine which NOS isoform was
predominately responsible for this increase in NOS-derived superox-
ide. Previously, LPS treatment had been shown to reduce mRNA
expression and decrease eNOS protein expression in bovine endo-
thelial cells [96] and 12 h post-LPS treatment in the mouse lung [97].
As ADMA is associated with eNOS uncoupling [46], it may be possible
that eNOS is involved in superoxide and peroxynitrite generation in
ALI, leading to protein nitration associated with lung leak in ALI.
Peroxynitrite scavengers reduced the nitrated protein levels and
decreased capillary leakage. However, further investigation into the
individual role of eNOS in ALI is warranted.
Hypoxia associated with proinflammatory mediators in ARDS
augments the formation of ROS by increased NADPH oxidase
expression. In ARDS an increase in eNOS expression is observed,
which may be caused by mechanical ventilation leading to Akt-
mediated phosphorylation [98]. The concomitant upregulation of
eNOS and NADPH oxidase results in increased ONOO− formation and
may advance ARDS by promoting tissue damage and inflammation
[99]. Therefore, specific antioxidants targeting eNOS uncoupling and/
or its triggers could be an interesting therapeutic approach to ARDS.
eNOS uncoupling during thoracic surgery
As described above, NO is not only a vasodilator, it also inhibits
platelet aggregation, thrombus formation, and smooth muscle cell
proliferation and therefore may interfere with cardiovascular out-
come. A lack of NO due to eNOS uncoupling may negatively affect
postoperative patient outcome. The effects of NO metabolism and
eNOS uncoupling have been thoroughly investigated in coronary
artery bypass graft surgery (CABG) and lung transplantation.
CABG surgery
Conventional stripping of the saphenous vein is associated with
more damage to the endothelium and the tunica adventitia and lower
eNOS levels in venous endothelium than atraumatic harvesting, by
which the surrounding tissue is spared [100]. Impaired NO synthesis
due to endothelial damage during graft harvesting may cause early
graft failure [101]. Together with an increase in growth factors after
ischemia and reperfusion (IR), this diminished NO effect results in
neointimal hyperplasia, reduced lumen diameter, and decreased
coronary blood flow, which are associated with later stages of graft
failure. This may influence the long-term outcome of CABG proce-
dures. Modulating eNOS uncoupling in the cardioplegia solution may
also be an adequate approach to preventing CABG failure by
endothelial dysfunction. Maintenance of normal NO homeostasis is
an important factor in protecting the graft and the heart from IR injury
during cardioplegia [102]. Interindividual differences in recuperation
from CABG procedure are not dependent on polymorphisms of the
eNOS gene, as these do not have any influence on early postoperative
hemodynamics after cardiac surgery [103]. Therefore, addition of BH4
and L-arginine may prevent eNOS uncoupling, decrease inflammation,
and prevent graft failure [102].
Lung transplantation
Lung preservation, transplantation, and reperfusion lead to
reduced endogenous NO production in lung tissue, indicated by a
decreased amount of exhaled NO [104]. Liu et al. [105] investigated
the effects of eNOS on lung transplantation surgery in the rat. They
demonstrated a reduction in eNOSmRNA during lung transplantation,
which was possibly caused by a lower ability of the endothelial and
lung epithelial cell to respond appropriately to ischemia and
reperfusion. Transplanted lungs had decreased bioavailability of NO.
IR may have a direct effect on eNOS synthesis and degradation,
contributing to injury in lung transplants. Administration of the NO
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endothelial injury in alveolar and bronchial epithelial cells in an ex
vivo rat lung perfusion model [106]. Administration of the eNOS
cofactor BH4 during lung allograft reperfusion in a pig model of lung
transplantation reduced posttransplantation lung edema and oxygen-
derived free radical injury in the graft [107]. Exogenous administra-
tion of NO by inhalation from cylinders containing nitrogen for 84 h
on average (15–217 h) after bilateral lung transplantation reduced
early severe graft dysfunction, as indicated by a decrease in hypoxia
and PAH. Also, these patients needed shorter postoperative mechan-
ical ventilation, had fewer airway complications, and had a decrease
in general mortality [108].
Wound healing
Vasodilation and hyperemia of existing vessels, both NO-mediated
processes, are coincident with angiogenesis [109]. Newly formed
vessels deliver the necessary metabolic substances to the regenerat-
ing tissue to assist wound repair. Closure of the wound is mediated by
both wound contraction and wound reepithelialization. The effects of
vascular endothelial growth factor (VEGF), one of the key mediators
of angiogenesis, are mediated by NO [110]. VEGF upregulates eNOS
protein levels and NO production [111], and activation of VEGFR-2
results in upregulation and phosphorylation of eNOS and increased
NO production by inducing a peak in intracellular Ca2+ levels [112]. In
eNOS−/− mice, closure of excisional wounds where a square piece of
skin was removed was significantly impaired, and healed cephalad-
to-caudal incisional wounds developed less tensile strength [113].
This may be of therapeutic importance in such diseases as diabetes
mellitus in which a deficit in VEGF expression is part of the associated
defect in wound healing [114].
Modulating the eNOS pathway
L-Arginine
L-Arginine is the primary substrate for endothelial NO production
by eNOS and supplementation can improve endothelial-derived
dilatation, decrease adhesion of platelets and monocytes, and reduce
systemic and pulmonary artery pressure [115]. A lack of L-arginine
may lead to eNOS uncoupling. L-Arginine is broken down by arginases
that compete with eNOS for their common substrate [44]. In
pulmonary endothelium of patients with pulmonary artery hyper-
tension [45] and in endothelial cells of the corpus cavernosum of
diabetes patients [49], arginase expression indeed seems to be
upregulated. Therefore, the L-arginine deficiency in endothelial
dysfunction can be explained as a very local and relative lack of this
amino acid, situated in the direct vicinity of eNOS by an upregulation
of L-arginase [49]. This could be a partial explanation of the beneficial
effect of L-arginine supplementation observed in some, but not all,
clinical studies [116]. In addition, L-arginine can also serve as a direct
radical scavenger [117] and compete with the endogenous eNOS
inhibitor ADMA [46].
Three days of oral L-arginine administration to young men with
CAD showed improvement in endothelium-dependent vasodilatation
and reduced monocyte adhesion [118]. In patients with heart failure,
oral administration of L-argininewas shown to improve renal function
[119], vascular function, and cardiac output [120]. In hypercholester-
olemic patients administration of L-arginine improved endothelium-
dependent forearm dilatation [121], just as effectively as statin
therapy [122]. In addition, some patients with PAH benefit from
intravenous infusion of L-arginine, as it increases L-arginine and
L-citrulline concentrations and has a potent short-term vasodilating
effect, equal to prostacyclin but better tolerated, reducing pulmonary
artery pressure [123]. However, most of the positive studies
investigating L-arginine supplementation were rather short. Incontrast, L-arginine may not be beneficial if given chronically, as
shown in the VINTAGE MI study [124]. Nevertheless, this study has
been criticized for serious flaws [125]. A meta-analysis concluded that
short-term L-arginine treatment improved endothelial function in
only those individuals with endothelial dysfunction, as determined
with flow-mediated vasodilation [116].
BH4
BH4 is an FDA-approved therapy for some forms of phenylketon-
uria, in which there is a deficiency in the hepatic enzyme
phenylalanine hydroxylase. Furthermore, BH4 is of critical importance
in stabilizing the eNOS dimer, keeping it in coupled form, allowing
eNOS to function appropriately. In addition, oral administration of BH4
after acute myocardial infarction induction in rat heart attenuates the
remodeling and preserves cardiac function by decreasing superoxide
generation [77]. Reduction of the eNOS dimer/monomer ratio after MI
in these rats and its restoration by exogenous BH4 indicated the
occurrence and subsequent alleviation of eNOS uncoupling. BH4 has
been shown to improve endothelial dysfunction in patients with DM 2
[126], heart transplant patients treated with cyclosporine A [127], and
patients with inflammatory disorders such as rheumatoid arthritis
[128]. BH4 was also found to lower blood pressure [129] but longer
term studies have failed to show any significant benefit [130]. BH4 is
temperature and light unstable, very hygroscopic, and quickly
oxidized, as it is an antioxidant, and therefore difficult in practical
use as a chronic drug treatment. The BH4 analogue sapropterin
hydrochloride (BioMarin Pharmaceuticals, CA, USA) does not have
these stability problems.
Folic acid
Folic acid has direct superoxide scavenging effects [131] and
increases the bioavailability of BH4 in the vasculature by preventing
its oxidation [132] and ensuring eNOS coupling. Chronic administra-
tion of 5-MTHF, the active form of folic acid, improves endothelial
function in patients with systolic heart failure [133], reverses eNOS
dysfunction and uncoupling in NTG-treated patients [84], and can
restore endothelial function in hypercholesterolemic patients [134].
High-dose folic acid administration to patients with CAD showed no
more improved vascular function compared to a low-dose treatment
of folic acid [135]. No human data yet are available about the effects of
folic acid on myocardial dysfunction.
Other eNOS-modulating agents
Statins have been reported to increase eNOS stability and its
expression on the cell membrane in addition to their well-known
LDL-lowering effect [136]. Statins activate adenosine receptors A1,
A2A, and A2B, which leads to Akt-mediated eNOS phosphorylation
[137]. The cardioprotective effects of angiotensin converting enzym
inhibitors and angiotensin receptor blockers (ARBs) are alsomediated
by eNOS-generated NO. ACE inhibitors and ARBs activate eNOS by
stimulation of a PI3-kinase/Akt pathway [138]. Both statins and
modulators of the rennin–angiotensins system also inhibit NADPH
oxidases, potentially resulting in reduced eNOS uncoupling. Estrogens
increase eNOS phosphorylation and therefore its activity. This may be
an explanation for the lower incidence of atherosclerosis in
premenopausal women. Estradiol directly activates eNOS by binding
on the estrogen receptor and subsequently activates the cGMP-
dependent protein kinase G pathway, which phosphorylates the eNOS
enzyme [139]. This way, estradiol is a protective agent in IR injury, as
was demonstrated in lung tissue after trauma–hemorrhage [140]. A
therapeutic possibility for treatment of PAH is sildenafil, which in-
creases pulmonary vasodilatation [141]. Chronic use reduces pulmo-
nary arterial pressure in primary pulmonary hypertension, inhibits
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pulmonary hypoxic vasoconstriction in healthy volunteers by raising
cGMP [143], as reflected in higher plasma concentrations. Sildenafil
synergistically enhances the effectiveness of NO inhalation because
they both raise cGMP levels, as shown by a longer lasting and
quantitatively higher pulmonary vasodilatation, in both ventricular
insufficiency and pulmonary arterial hypertension. High doses of
vitamin C can acutely improve endothelial dysfunction. Its antioxidant
effects stabilize BH4, reducing the formation of its oxidation product
BH2 [144], and facilitate the recycling of BH4, independent of
superoxide scavenging [39]. Another eNOS modulator is AVE9488, a
so-called eNOS enhancer, which may serve as a new cardioprotectant,
as it improves left-ventricular remodeling and function and
diminishes endothelial dysfunction after experimental MI in rodents
[145,146]. No clinical data from AVE9488 are available yet.
Conclusion
During the past few years, eNOS uncoupling, and especially eNOS-
dependent superoxide generation, has been suggested as having a
major role in the pathogenesis of many cardiovascular and pulmonary
diseases, such as systemic and pulmonary artery hypertension, heart
failure, and ischemia/reperfusion injury. More research is needed to
further explore the triggers (i.e., sources of superoxide) that initiate
eNOS uncoupling. The possibility of targeting specific sources of ROS
has paved the way for various new therapeutic approaches. Recent
data have shown that by specifically targeting eNOS-dependent ROS
generation, eNOS uncoupling can not only be prevented but also be
reversed. Modulating eNOS uncoupling by eNOS modulators such as
BH4 and folic acid has been proven to be effective in the human
vasculature. More focused research is needed to extrapolate the
interesting preclinical data on these eNOS modulators to the human
myocardium and lung.
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